Colorectal Cancer
Experts
Contact us to join our network, learn more about our educational offerings, or inquire about joining our faculty. We are your source for up-to-date clinical information.
Want This Data Sent Straight To You?
Subscribe today and get credible, unbiased information from disease experts sent straight to your phone or inbox.
Johanna Bendell, MD Chief Development Officer Director, Drug Development Unit Nashville, Sarah Cannon Research Institute, Partner, Tennessee Oncology
Johanna Bendell, MD discusses the Destiny Gastric trial
Johanna Bendell, MD breaks down the randomized, Phase II, Destiny Gastric trial comparing fam-trastuzumab deruxtecan-nxki (DS-8201) versus physician’s choice of irinotecan or paclitaxel in previously treated patients with advanced, HER-2+, gastric or gastroesophageal junctional adenocarcinoma. Primary endpoint was Overall Response Rate (ORR).
“ This is the first positive data of a anti-HER2 drug that we have seen for gastric cancer to be successful since trastuzumab.
Gastric Cancer
Want This Data Sent Straight To You?
Subscribe today and get credible, unbiased information from disease experts sent straight to your phone or inbox.
CANT FIND WHAT YOU ARE LOOKING FOR?
GET IN TOUCH
Dr. Bendell joined Sarah Cannon in 2008 and serves as Chief Development Officer. In her role, Dr. Bendell leads the development and expansion of physician, site and Pharma relationships across the Sarah Cannon network. Additionally, Dr. Bendell serves as Director of the GI Cancer Research Program, overseeing the clinical trial menu for GI cancers across the Sarah Cannon network. Her work in early drug development has helped guide first-in-man agents through proof-of-concept studies.
Dr. Bendell received her undergraduate and medical degrees from the University of Chicago in 1994 and 1998, respectively. She completed her internship and residency in the Department of Internal Medicine at Brigham and Women’s Hospital in Boston, as well as a fellowship in adult oncology at Boston’s Dana-Farber Cancer Institute. She is board certified in medical oncology. Additionally, she is an associate with Tennessee Oncology, PLLC.